Greenwich LifeSciences Inc. (GLSI)
NASDAQ: GLSIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GLSI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $282.56M
- EPS (TTM)
- -$1.63
- Dividend yield
- None
- 52-week range
- 7.78 – 34.10
- Day range
- 18.40 – 20.20
- Volume / Avg
- 472.11K / 160.76K
- Beta
- —
- Shares outstanding
- 14.68M
52-week range
GLSI stock today
Greenwich LifeSciences (GLSI) closed at $19.25 on Nov 20, down 2.73% (-$0.54), versus the S&P 500's 3.70% decline. Volume was 2.9x the average at 472.11K shares, a sign of unusually heavy trading. Shares are 43.5% below their 52-week high of $34.10, set on Jan 27, 2026 and 147.4% above the 52-week low of $7.78, in the middle of the past year's range.
GLSI is down 8.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 136.2%. Greenwich LifeSciences has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Greenwich LifeSciences
Company profileGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Snehal S. Patel
- Headquarters
- Stafford, TX
- IPO year
- 2020
- Website
- greenwichlifesciences.com
Financial highlights
Full financialsGreenwich LifeSciences reported a net loss of $19.4 million, compared with a loss of $17.4 million a year earlier. Diluted earnings per share came in at -$1.43.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-19.36M | $-17.41M | $-8.89M | $-7.83M | $-4.57M |
| EPS (diluted) | $-1.43 | $-1.34 | $-0.69 | $-0.61 | $-0.35 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$57.50+198.70%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.30 vs $-0.30
- Surprise
- 0.00%
GLSI news
All GLSI newsGreenwich LifeSciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs GLSI |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs GLSI |
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs GLSI |
| EVMNEvommune Inc. | 7.04 | -2.76% | $291.10M | vs GLSI |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs GLSI |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs GLSI |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs GLSI |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs GLSI |
Indexes, lists and sector
Greenwich LifeSciences stock FAQ
What is Greenwich LifeSciences's stock price today?
GLSI last traded at $19.25 as of Nov 20, 4:00 PM EST, down 2.73% on the day. Prices are delayed at least 15 minutes.
Who is Greenwich LifeSciences's CEO?
Mr. Snehal S. Patel is the chief executive officer of Greenwich LifeSciences Inc..
What is the GLSI 52-week high?
The 52-week high for GLSI is $34.10 and the 52-week low is $7.78. The stock is currently 43.5% below its high.